Balaxi Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹58.37(-3.15%)April 25, 2025 15:53:57 PM IST
- NSE
- BSE
- Vol : 174.54K (NSE + BSE)Last 20 day avg : 408.04 K
Balaxi Pharmaceuticals is trading -3.15% lower at Rs 58.37 as compared to its last closing price. Balaxi Pharmaceuticals has been trading in the price range of 61.09 & 57.00. Balaxi Pharmaceuticals has given -19.28% in this year & -9.66% in the last 5 days. Balaxi Pharmaceuticals has TTM P/E ratio 17.53 as compared to the sector P/E of 22.83.The company posted a net profit of 5.36 Crores in its last quarter.Listed peers of Balaxi Pharmaceuticals include Themis Medicare (-5.19%), Ind-swift Laboratories (-6.82%), Brooks Laboratories (-4.92%).The Mutual Fund holding in Balaxi Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Balaxi Pharmaceuticals was at 16.02% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 27, 2025, 07:25 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.48The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values14.15Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility1.01Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.10The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
- R1
- 73.69
- R2
- 83.47
- R3
- 93.23
- S1
- 54.15
- S2
- 44.39
- S3
- 34.61
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Themis Medicare | Bearish | 132.50 | -5.19 | 1,226.89 | 28.29 | 3.25 | 0.37 | 7.09 |
| Ind-swift Laboratories | Bearish | 80.19 | -6.82 | 475.89 | 3.42 | 0.51 | - | 1.20 |
| Brooks Laboratories | Bullish | 140.00 | -4.92 | 412.40 | - | 5.6 | - | 0.54 |
| Balaxi Pharmaceuticals | Bearish | 58.37 | -3.15 | 322.25 | 13.32 | 1.48 | - | 0.87 |
| Ind Swift | Bearish | 13.09 | -3.04 | 70.47 | 3.78 | - | - |
Promoter(s) holds a high stake in the company at 65.99%- FIIs are invested in this company
FIIs holding has decreased by 0.46 percentage points from previous quarter- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-10 | Quarterly Results & Others |
| 2024-11-05 | Quarterly Results & Others |
| 2024-08-02 | Quarterly Results |
| 2024-05-29 | Audited Results |
| 2023-11-02 | Quarterly Results |
- IndustryMajor Drugs
- ISININE618N01022
- BSE Code
- NSE CodeBALAXI
Balaxi Pharmaceuticals is trading at 58.37 as on Fri Apr 25 2025 10:23:57. This is -3.15% lower as compared to its previous closing price of 60.27.
The market capitalization of Balaxi Pharmaceuticals is 322.25 Cr as on Fri Apr 25 2025 10:23:57.
The 52 wk high for Balaxi Pharmaceuticals is 151.45 whereas the 52 wk low is 50.42
Balaxi Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 17.53
- Sector P/E: 22.83
- Dividend Yield: 0.00%
- D/E ratio: -
Balaxi Pharmaceuticals reported a net profit of -2.39 Cr in 2024.